These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ehlers-Danlos syndrome IV due to a novel defect in type III procollagen. Pyeritz RE; Stolle CA; Parfrey NA; Myers JC Am J Med Genet; 1984 Nov; 19(3):607-22. PubMed ID: 6507506 [TBL] [Abstract][Full Text] [Related]
3. The Ehlers-Danlos syndromes. Yeowell HN; Pinnell SR Semin Dermatol; 1993 Sep; 12(3):229-40. PubMed ID: 8217561 [TBL] [Abstract][Full Text] [Related]
4. A novel point mutation at donor splice-site in intron 42 of type III collagen gene resulting in the inclusion of 30 nucleotides into the mature mRNA in a case of vascular type of Ehlers-Danlos syndrome. Okita H; Ikeda Y; Mitsuhashi Y; Namikawa H; Kitamura Y; Hamasaki Y; Yamazaki S; Hatamochi A Arch Dermatol Res; 2010 Jul; 302(5):395-9. PubMed ID: 19543901 [TBL] [Abstract][Full Text] [Related]
5. Abnormal formation of collagen cross-links in skin fibroblasts cultured from patients with Ehlers-Danlos syndrome type VI. Pasquali M; Still MJ; Vales T; Rosen RI; Evinger JD; Dembure PP; Longo N; Elsas LJ Proc Assoc Am Physicians; 1997 Jan; 109(1):33-41. PubMed ID: 9010914 [TBL] [Abstract][Full Text] [Related]
6. Ehlers-Danlos syndromes and Marfan syndrome. Callewaert B; Malfait F; Loeys B; De Paepe A Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):165-89. PubMed ID: 18328988 [TBL] [Abstract][Full Text] [Related]
7. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. De Paepe A; Malfait F Br J Haematol; 2004 Dec; 127(5):491-500. PubMed ID: 15566352 [TBL] [Abstract][Full Text] [Related]
8. [Ehlers-Danlos syndrome--diagnosis and subclassification]. Rand-Hendriksen S; Wekre LL; Paus B Tidsskr Nor Laegeforen; 2006 Aug; 126(15):1903-7. PubMed ID: 16915311 [TBL] [Abstract][Full Text] [Related]
9. The molecular basis of classic Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients. Malfait F; Coucke P; Symoens S; Loeys B; Nuytinck L; De Paepe A Hum Mutat; 2005 Jan; 25(1):28-37. PubMed ID: 15580559 [TBL] [Abstract][Full Text] [Related]
10. Absence of inferior labial and lingual frenula in Ehlers-Danlos syndrome: a minor diagnostic criterion in French patients. Machet L; Hüttenberger B; Georgesco G; Doré C; Jamet F; Bonnin-Goga B; Giraudeau B; Maruani A; Laure B; Vaillant L Am J Clin Dermatol; 2010; 11(4):269-73. PubMed ID: 20143893 [TBL] [Abstract][Full Text] [Related]
11. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. Malfait F; Symoens S; De Backer J; Hermanns-Lê T; Sakalihasan N; Lapière CM; Coucke P; De Paepe A Hum Mutat; 2007 Apr; 28(4):387-95. PubMed ID: 17211858 [TBL] [Abstract][Full Text] [Related]
12. The Ehlers-Danlos syndrome, a disorder with many faces. De Paepe A; Malfait F Clin Genet; 2012 Jul; 82(1):1-11. PubMed ID: 22353005 [TBL] [Abstract][Full Text] [Related]
13. A translocation interrupts the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Toriello HV; Glover TW; Takahara K; Byers PH; Miller DE; Higgins JV; Greenspan DS Nat Genet; 1996 Jul; 13(3):361-5. PubMed ID: 8673139 [TBL] [Abstract][Full Text] [Related]
14. Further evidence that the failure to cleave the aminopropeptide of type I procollagen is the cause of Ehlers-Danlos syndrome type VII. Ho KK; Kong RY; Kuffner T; Hsu LH; Ma L; Cheah KS Hum Mutat; 1994; 3(4):358-64. PubMed ID: 8081389 [TBL] [Abstract][Full Text] [Related]
15. The mRNA and the activity of lysyl hydroxylase are up-regulated by the administration of ascorbate and hydralazine to human skin fibroblasts from a patient with Ehlers-Danlos syndrome type VI. Yeowell HN; Walker LC; Marshall MK; Murad S; Pinnell SR Arch Biochem Biophys; 1995 Aug; 321(2):510-6. PubMed ID: 7646078 [TBL] [Abstract][Full Text] [Related]
16. Decreased expression of lysyl hydroxylase 2 (LH2) in skin fibroblasts from three Ehlers-Danlos patients does not result from mutations in either the coding or proximal promoter region of the LH2 gene. Walker LC; Teebi AS; Marini JC; De Paepe A; Malfait F; Atsawasuwan P; Yamauchi M; Yeowell HN Mol Genet Metab; 2004 Dec; 83(4):312-21. PubMed ID: 15589118 [TBL] [Abstract][Full Text] [Related]
17. COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers-Danlos syndrome. Symoens S; Malfait F; Renard M; André J; Hausser I; Loeys B; Coucke P; De Paepe A Hum Mutat; 2009 Feb; 30(2):E395-403. PubMed ID: 18972565 [TBL] [Abstract][Full Text] [Related]
18. [Various characteristics of the structure and synthesis of procollagens produced by cultured skin fibroblasts from patients with Danlos-Ehlers syndrome type I]. Sokolov BP; Sher BM; Lomova TIu; Kukharenko VI; Blinnikova OE Mol Gen Mikrobiol Virusol; 1987 Jan; (1):19-23. PubMed ID: 3561422 [TBL] [Abstract][Full Text] [Related]
19. Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications. Beridze N; Frishman WH Cardiol Rev; 2012; 20(1):4-7. PubMed ID: 22143279 [TBL] [Abstract][Full Text] [Related]
20. [Ehlers-Danlos syndromes. Clinical, genetic and molecular aspects]. Germain D Ann Dermatol Venereol; 1995; 122(4):187-204. PubMed ID: 8526413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]